Latest Ratios: P/E Ratio 20.5x · EV/EBITDA 8.0x · ROE 12.1%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $382M | $399M | $273M | $337M | $161M | $376M | $299M | $176M | $156M | $218M | $286M |
| Enterprise Value | $307M | $324M | $202M | $269M | $120M | $313M | $233M | $149M | $107M | $189M | $263M |
| P/E Ratio → | 20.52 | 20.36 | 36.65 | 22.45 | — | 13.03 | 13.97 | 26.26 | — | — | 136.36 |
| P/S Ratio | 0.80 | 0.83 | 0.60 | 0.76 | 0.38 | 0.85 | 0.77 | 0.48 | 0.43 | 0.64 | 0.84 |
| P/B Ratio | 2.49 | 2.47 | 1.70 | 2.11 | 1.09 | 2.33 | 1.90 | 1.36 | 1.29 | 1.82 | 2.16 |
| P/FCF | 13.26 | 13.82 | 19.05 | 10.95 | — | 13.46 | 9.11 | 51.03 | 9.17 | 43.42 | — |
| P/OCF | 10.83 | 11.28 | 10.79 | 8.16 | 226.47 | 10.87 | 7.93 | 20.55 | 7.14 | 20.72 | 83.65 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.67 | 0.45 | 0.60 | 0.28 | 0.70 | 0.60 | 0.41 | 0.29 | 0.55 | 0.77 |
| EV / EBITDA | 7.97 | 8.38 | 5.90 | 8.80 | 3.76 | 6.83 | 7.22 | 5.56 | 7.00 | 18.85 | 17.75 |
| EV / EBIT | 12.43 | 10.82 | 10.90 | 13.28 | 7.76 | 9.75 | 10.15 | 9.48 | 29.76 | 136.17 | 26.25 |
| EV / FCF | — | 11.22 | 14.13 | 8.75 | — | 11.20 | 7.11 | 43.19 | 6.28 | 37.60 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.4% | 72.4% | 71.5% | 72.1% | 71.0% | 74.0% | 73.7% | 74.1% | 73.8% | 73.4% | 73.3% |
| Operating Margin | 5.2% | 5.2% | 4.4% | 4.2% | 3.9% | 7.8% | 5.6% | 4.5% | 1.5% | 0.4% | 2.9% |
| Net Profit Margin | 4.1% | 4.1% | 1.7% | 3.4% | -0.1% | 6.5% | 5.5% | 1.9% | -0.2% | -3.8% | 0.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.1% | 12.1% | 4.8% | 9.8% | -0.3% | 18.1% | 14.9% | 5.4% | -0.7% | -10.3% | 1.6% |
| ROA | 7.8% | 7.8% | 3.1% | 6.3% | -0.2% | 11.4% | 9.2% | 3.3% | -0.4% | -6.5% | 1.1% |
| ROIC | 21.0% | 21.0% | 16.5% | 14.2% | 11.9% | 27.4% | 16.6% | 13.9% | 5.0% | 1.0% | 7.3% |
| ROCE | 13.8% | 13.8% | 11.5% | 11.1% | 9.4% | 19.2% | 12.8% | 11.5% | 4.0% | 1.0% | 6.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.09 | 0.09 | 0.13 | 0.14 | 0.17 | 0.21 | 0.01 | 0.11 | 0.07 |
| Debt / EBITDA | 0.49 | 0.49 | 0.41 | 0.49 | 0.60 | 0.50 | 0.82 | 1.00 | 0.10 | 1.37 | 0.67 |
| Net Debt / Equity | — | -0.46 | -0.44 | -0.42 | -0.28 | -0.39 | -0.42 | -0.21 | -0.41 | -0.24 | -0.17 |
| Net Debt / EBITDA | -1.94 | -1.94 | -2.05 | -2.21 | -1.28 | -1.38 | -2.04 | -1.01 | -3.22 | -2.92 | -1.51 |
| Debt / FCF | — | -2.60 | -4.92 | -2.19 | — | -2.26 | -2.01 | -7.83 | -2.89 | -5.82 | — |
| Interest Coverage | 305.20 | 305.20 | 127.21 | 293.78 | 62.10 | 128.29 | 224.74 | 364.77 | 9.27 | 4.80 | 627.44 |
Net cash position: cash ($94M) exceeds total debt ($19M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.28 | 2.28 | 2.44 | 2.16 | 2.28 | 2.15 | 2.21 | 1.94 | 1.60 | 1.91 | 1.59 |
| Quick Ratio | 1.41 | 1.41 | 1.54 | 1.29 | 1.24 | 1.35 | 1.53 | 1.14 | 0.97 | 1.09 | 0.83 |
| Cash Ratio | 1.20 | 1.20 | 1.29 | 1.07 | 0.92 | 1.12 | 1.32 | 0.93 | 0.76 | 0.80 | 0.54 |
| Asset Turnover | — | 1.84 | 1.89 | 1.78 | 1.84 | 1.72 | 1.54 | 1.70 | 1.89 | 1.75 | 1.66 |
| Inventory Turnover | 1.94 | 1.94 | 2.18 | 1.86 | 1.80 | 1.90 | 2.12 | 2.01 | 2.28 | 2.07 | 1.91 |
| Days Sales Outstanding | — | 6.54 | 7.61 | 7.23 | 12.20 | 7.29 | 6.99 | 7.38 | 7.75 | 9.48 | 8.28 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 5.3% | — | — | — | 0.8% | 2.6% |
| Payout Ratio | — | — | — | — | — | 68.8% | — | — | — | — | 351.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.9% | 4.9% | 2.7% | 4.5% | — | 7.7% | 7.2% | 3.8% | — | — | 0.7% |
| FCF Yield | 7.5% | 7.2% | 5.2% | 9.1% | — | 7.4% | 11.0% | 2.0% | 10.9% | 2.3% | — |
| Buyback Yield | 4.3% | 4.1% | 3.2% | 1.9% | 8.4% | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 4.3% | 4.1% | 3.2% | 1.9% | 8.4% | 7.3% | 0.0% | 0.0% | 0.0% | 0.8% | 2.6% |
| Shares Outstanding | — | $18M | $19M | $19M | $19M | $20M | $20M | $20M | $19M | $19M | $19M |
Consultant network churn volatility
According to current market data, NATR trades at a P/E of 19.83, which appears to reflect a complexity discount relative to broader consumer defensive peers, potentially overlooking the firm's unique manufacturing-led competitive advantage and its transition toward a more sustainable direct-to-consumer digital sales model.
The current forward P/E of 17.44 suggests that investors are pricing in significant skepticism regarding the company's ability to scale operating margins. While the valuation is lower than some peers, it warrants further investigation into whether the market is correctly valuing the company's high cash-to-market-cap ratio or simply applying a blanket discount for the direct-selling business model.
Based on reported figures, ROIC has fluctuated between 3.3% and 7.6% over the last ten quarters, suggesting that Nature's Sunshine is struggling to consistently compound returns on its invested capital despite maintaining a structurally superior gross margin profile compared to many of its direct-selling industry peers.
The volatility in ROIC appears driven by inconsistent operating margins rather than capital intensity, as the company maintains a relatively lean asset base. Investors should monitor whether recent digital transformation investments begin to drive a more stable upward trend in capital returns or if these outlays continue to dilute overall efficiency.
As reported in financial statements, the company's cash conversion cycle remains elevated, reaching 156 days in 2026Q1, primarily due to high inventory days that suggest potential inefficiencies in managing product stock levels relative to the fluctuating demand from the independent consultant sales force.
The persistent inventory days, which have remained well above 160 for most of the trailing ten quarters, indicate that the company may be carrying excess stock to mitigate supply chain risks. This working capital drag appears to be a primary factor in the inconsistent free cash flow generation observed across recent periods.
According to recent SEC filings, Nature's Sunshine maintains a debt-to-equity ratio of 0.13, a conservative posture that provides a significant buffer against the operational volatility inherent in the direct-selling sector and distinguishes the firm from more highly leveraged competitors who face greater refinancing risks.
The company's minimal reliance on debt suggests that it is well-positioned to navigate potential regulatory or macroeconomic headwinds without the pressure of interest coverage constraints. This financial flexibility appears to be a strategic choice, allowing the firm to prioritize internal reinvestment over debt service obligations.
The P/E ratio is frequently misapplied to Nature's Sunshine, as it fails to account for the significant cash reserves and the high-margin, recurring nature of the company's botanical manufacturing operations, which are often obscured by the volatile earnings profile typical of direct-selling organizations.
Investors should instead focus on EV/EBITDA or P/FCF, as these metrics better capture the company's true earning power by stripping out the noise of non-operating items and the impact of cash accumulation. Relying solely on P/E may lead to an inaccurate assessment of the firm's valuation, particularly given the potential for future capital allocation events.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NATR stock.
Nature's Sunshine Products, Inc.'s current P/E ratio is 20.5x. The historical average is 28.4x. This places it at the 54th percentile of its historical range.
Nature's Sunshine Products, Inc.'s current EV/EBITDA is 8.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 8.2x.
Nature's Sunshine Products, Inc.'s return on equity (ROE) is 12.1%. The historical average is 10.8%.
Based on historical data, Nature's Sunshine Products, Inc. is trading at a P/E of 20.5x. This is at the 54th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Nature's Sunshine Products, Inc. has 72.4% gross margin and 5.2% operating margin.
Nature's Sunshine Products, Inc.'s Debt/EBITDA ratio is 0.5x, indicating low leverage. A ratio below 2x is generally considered financially healthy.